Free Trial
→ Why major institutions are piling into this digital asset now (From Awesomely) (Ad)tc pixel
NASDAQ:BMEA

Biomea Fusion Q3 2026 Earnings Date & Estimates

Biomea Fusion logo
$1.26 -0.10 (-7.35%)
Closing price 10/13/2026 04:00 PM Eastern
Extended Trading
$1.03 -0.23 (-18.25%)
As of 08:42 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biomea Fusion is estimated to report Q3 2026 earnings on Tuesday, November 3, 2026, before market opens. The conference call is scheduled for October 30, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Biomea Fusion in Q3 2026

Biomea Fusion is expected to post earnings of -$0.21 per share. In the same quarter a year earlier Biomea Fusion reported -$0.27 per share. Biomea Fusion last reported on August 5, 2026, posting -$0.12 per share and beating the -$0.2235 consensus estimate. Biomea Fusion has beaten the consensus EPS estimate in 6 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.21
Prior-Year EPS
-$0.27

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.12 (Beat by +$0.1035)
EPS Beat Rate
6 of last 8 quarters

Prepare for the Q3 2026 Call

Biomea Fusion Q3 2026 Earnings FAQ

Biomea Fusion (NASDAQ:BMEA) is estimated to report Q3 2026 earnings on Tuesday, November 3, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Biomea Fusion's Q3 2026 earnings conference call is scheduled for Friday, October 30, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Biomea Fusion to post earnings of -$0.21 per share for Q3 2026.

Biomea Fusion Earnings Headlines

Biomea Reports Phase 1 Weight-Loss Data For Oral GLP-1 Candidate BMF-650; Shares Fall
October 13 at 12:58 AM  |  rttnews.comhttps://www.rttnews.com/3698694/biomea-reports-phase-1-weight-loss-data-for-oral-glp-1-candidate-bmf-650-shares-fall.aspx
Biomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss Transcript
October 13 at 9:00 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4953931-biomea-fusion-inc-bmea-discusses-bmfminus-650-phase-i-topline-results-and-potential-for
I'm giving you a space stock today. Free.
On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any regular brokerage account gives investors exposure to SpaceX and 66 of its neighbors, without an IPO allocation. He is also naming two space stocks he would consider dumping before December, plus a $14 stock that Elon has personally put his name on.tc pixel
October 14 at 1:00 AM  |  Behind the Markets (Ad)
Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist
October 13 at 4:08 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/13/3380154/0/en/biomea-fusion-announces-phase-1-results-for-bmf-650-its-investigational-next-generation-oral-small-molecule-glp-1-receptor-agonist.html
Biomea Shares Rise Ahead Of Phase I Data Readout For Obesity Drug BMF-650
October 13 at 9:50 AM  |  rttnews.comhttps://www.rttnews.com/3698432/biomea-shares-rise-ahead-of-phase-i-data-readout-for-obesity-drug-bmf-650.aspx
Brookline Capital Markets Estimates Biomea Fusion Q3 Earnings
October 11 at 1:14 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31106750
See More Biomea Fusion Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biomea Fusion? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biomea Fusion and other key companies, straight to your email.

About Biomea Fusion

Biomea Fusion (NASDAQ:BMEA) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for serious diseases with significant unmet medical needs. The company’s research platform is centered on covalent chemistry, an approach designed to create potentially durable interactions between medicines and their biological targets.

Biomea’s lead investigational product is icovamenib, formerly known as BMF-219, an oral covalent menin inhibitor. The company has evaluated icovamenib in oncology indications, including certain blood cancers, and is also investigating its potential in metabolic diseases such as diabetes. Biomea’s pipeline and development programs are subject to clinical testing and regulatory review, and its investigational products have not been approved for commercial use.

Founded in 2017 and headquartered in Redwood City, California, Biomea Fusion became a publicly traded company in 2021. The company’s operations are primarily focused on research, clinical development and collaboration with medical and regulatory organizations in support of its drug candidates. Thomas Butler serves as Biomea Fusion’s chairman and chief executive officer.

View Biomea Fusion Profile
Earnings Tools